
VERU
USDVeru Inc. Common Stock
السعر في الوقت الحقيقي
مخطط الأسعار
المقاييس الرئيسية
مقاييس السوق
الافتتاح
$2.580
الأعلى
$2.650
الأدنى
$2.580
الحجم
0.18M
أساسيات الشركة
القيمة السوقية
42.5M
الصناعة
التكنولوجيا الحيوية
البلد
United States
إحصاءات التداول
متوسط الحجم
0.18M
البورصة
NCM
العملة
USD
نطاق 52 أسبوعاً
تقرير تحليل الذكاء الاصطناعي
آخر تحديث: ١٠ نوفمبر ٢٠٢٥VERU Stock Analysis: Veru Inc. Navigates Volatility Amid Fundamental Challenges
Market Snapshot
Current Price: $2.61 (as of 2025-11-10) 52-Week Range: $2.42 - $14.20 Market Cap: $41.89M | P/E Ratio: -9.00 Recent Volatility: Sharp decline from $4.43 (Oct 20) to $2.61, with erratic volume patterns
Recent Performance: Turbulent Descent
Veru’s stock has been in a clear downtrend since mid-October, shedding 41% from its October peak. Key observations:
- Public Offering Impact: The $25M offering on Oct 30 likely triggered selling pressure, with shares dropping 12% the following day.
- Volume Anomalies: Unusually high trading volume on Oct 30 ($765,700) and Nov 3 ($489,500) suggests panic selling or institutional exits.
- Support Zone: Recent closes near $2.52-$2.58 align with its 52-week low, indicating this range may act as temporary support.
Technical Signals: Mixed Messages
- Bullish DMI: +DI (15.4) > -DI (14.1) with ADX at 19.0 implies a weak uptrend could form if buyers step in.
- Volume Surge: 1.9x average volume on Nov 10 hints at renewed interest, but this could reflect short-term positioning rather than sustainable demand.
- MACD Death Cross: Bearish momentum confirmed as MACD (0.0119) fell below signal line (0.0162) despite AI’s upward projections.
Fundamentals: Value Trap or Hidden Potential?
- Contradictory Valuation: While the P/E (-9.00) appears broken due to negative earnings, the recommendation claims it’s “0.4x industry average” (likely referencing EBITDA multiples or forward estimates). Proceed with skepticism.
- **High-Risk
أخبار ذات صلة
Veru to Present Two Abstracts at ObesityWeek 2025
MIAMI, FL, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory
Veru Announces Pricing of $25 Million Public Offering
MIAMI, FL, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory
تنبؤ الذكاء الاصطناعيBeta
توصية الذكاء الاصطناعي
تم التحديث في: ١٠ نوفمبر ٢٠٢٥، ٠٢:٤٢ م
58.4% الثقة
المخاطر والتداول
نقطة الدخول
$2.52
جني الأرباح
$2.61
وقف الخسارة
$2.30
العوامل الرئيسية
أسهم ذات صلة
CHX
ChampionX Corporation
KRP
Kimbell Royalty Partners Common Units Representing Limited Partner Interests
DHCNI
Diversified Healthcare Trust 5.625% Senior Notes due 2042
COCP
Cocrystal Pharma Inc.
CW
Curtiss-Wright Corporation
ابق على اطلاع
تعيين تنبيهات الأسعار، الحصول على تحديثات تحليل الذكاء الاصطناعي وأخبار السوق في الوقت الحقيقي.